In clinical practice, microbial etiology of Community-Acquired Pneumonia (CAP) remains unknown in at least 60% of the cases [1]. Although there is a lack of scientific evidence that etiological identification improves individual patient outcomes, there are some reasons why we tend to investigate (the possibility of finding a resistant pathogen or an agent with public health implications; the aim of narrowing the treatment spectrum; and the ongoing knowledge of local epidemiology) [2].
